Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03734991 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
NCT03734991 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 376 participants.
The verdict
NCT03734991, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
Interventions
- DRUG Placebo
- DRUG Ibrexafungerp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03734991
The ClinicalTrials.gov registry entry for NCT03734991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03734991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03734991 about?
NCT03734991 is a clinical study titled "Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)". This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
What is the current status of trial NCT03734991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2019-01-04. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT03734991?
The interventions under investigation include: Placebo (DRUG), Ibrexafungerp (DRUG).
Who is sponsoring clinical trial NCT03734991?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.